Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bear Stearns Healthcare Conference In Brief

Executive Summary

One Swiss pharma company?: Novartis continues "to indicate to Roche that it might be a good idea for us to sit down and talk and I think as late as last Sunday, the Roche CEO continues to say that it's absolutely out of the question and not on the table," General Manager Kurt Graves says during Bear Stearns healthcare conference in New York City Sept. 17. "I would say it's remained consistent for over a year." Novartis' purchase of a 20% stake in Roche a year ago sparked rumors that Novartis was interested in partnering with its Swiss neighbor (1"The Pink Sheet" May 14, 2001, p. 11)...

You may also be interested in...



Pfizer To Re-Do Celebrex GI Outcome Study After Pharmacia Merger

Pfizer's post-merger plans for Celebrex include a second gastrointestinal outcomes study to demonstrate a safety benefit for the COX-2 inhibitor

Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance

The approval of Novartis' Zelnorm reflects FDA's comfort with an active surveillance program proposed by the company - and the extensive post marketing safety database of the irritable bowel syndrome agent in overseas markets

Rx Stock Declines Leave Novartis, P&G With More Options

Novartis is riding high expectations for the COX-2 inhibitor Prexige to a new level of prestige on Wall Street

Related Content

UsernamePublicRestriction

Register

PS040491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel